Abstract
Purpose :
To explore the real-world clinical outcomes in patients with a history of glaucoma treated with sustained-release dexamethasone intraocular suspension 9% for inflammation control following cataract surgery.
Methods :
Retrospective data were collected from records of patients at multiple surgical sites who received dexamethasone intraocular suspension at the end of cataract surgery between Mar 12 and Dec 15, 2019. Anterior chamber cell (ACC) and intraocular pressure (IOP) at postop days 1, 8, 14, and 30 were summarized, along with minimally invasive glaucoma surgery (MIGS) procedures and number of concomitant IOP-lowering medications.
Results :
641 eyes of 527 patients treated with dexamethasone intraocular suspension were included in the study; glaucoma history was reported for 80 eyes of 66 patients. 15 of these eyes had a MIGS procedure; mean (SD) IOP-lowering medications per eye was 1.4 (0.53). For those with a record at each visit, mean (SD) IOP was 18.5 (8.50), 14.3 (4.34), 15.3 (3.31), and 14.4 (3.51) mmHg at postop days 1, 8, 14, and 30; ACC clearing at these timepoints was present in 52%, 68%, 82%, and 90% of eyes. In the full study population, IOP at the same timepoints was 18.6 (6.69), 15.2 (4.51), 15.1 (3.86), and 14.1 (3.84) mmHg; and 40%, 65%, 85%, and 90% of eyes had no ACC.
Conclusions :
Results in this subset of eyes provide real-world insight into the use of a sustained release intraocular corticosteroid in patients with glaucoma undergoing cataract surgery; antiinflammatory efficacy and safety with regard to IOP elevation were similar to the full study population.
This is a 2021 ARVO Annual Meeting abstract.